Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Technology appraisal guidance
Reference number: TA256
Published: 23 May 2012
Last updated: 02 July 2021

Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer

Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer

Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer
30 March 2012
(173.71 Kb 50 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 29 March 2012